Shop Antibodies
Recombinant CD3-CD19 Bispecific Antibody Production

Recombinant CD3-CD19 Bispecific Antibody Production

Top panel: diagrams showing 2nd generation bispecific antibody protein domain arrangements featuring scFv domain from anti-CD3 and anti-CD19. Bottom panel: diagram showing the lentiviral vector design allowing single-step transfection and expression of knob-hole IgG molecule. Sequential His and Flag columns facilitate the purification of knob-hole bispecific antibody.

Recombinant CD3-CD19 Bispecific Antibody

$605.00 – $4,150.00

Item Cat No.: BCBI11

Antibody: Bispecific Antibody

Concentration: 0.50 mg/ml

Application: In vitro and In vivo

Reactivity: Human

Recombinant CD3-CD19 Bispecific Antibody is a chimeric anti-CD3 (ε) and anti-CD19 bispecific antibody consisting of the scFv domain sequences of anti-CD3 (ε) and anti-CD19 moieties and the Fc domain sequence of human IgG1.

BiCell Scientific Inc’s CD3-CD19 bispecific antibody is recombinant chimeric antibody that combines the scFv domains of Teplizumab (anti-CD3ε) and Inebilizumab (anti-CD19) with the Fc domain of human IgG1. Such a feature allows the chimeric antibody to retain the original binding characteristics of both Teplizumab and Inebilizumab on a single IgG1 molecule.

Isotype: Human IgG1

Class: Recombinant bispecific

Immunogen: CD3 (ε) and CD19

Production platform: CHO cells

Purification: Affinity chromatography

Storage buffer: PBS, pH 7.2

Storage condition: –20°C

For Research Use Only. Not for use in clinical diagnostics or therapeutics.

Additional information

Antibody Production Scale

50 ug, 250 ug, 1 mg

Reviews

There are no reviews yet.

Be the first to review “Recombinant CD3-CD19 Bispecific Antibody”

Related products

"I am really impressed with your approach. We tried multiple times previously to create monoclonal and polyclonal antibodies to claudin-2 and MLCK1. We have had limited success generating polyclonals and no success generating monoclonals. You have generated outstanding monoclonals to both. I look forward to continuing to work with you."

Jerrold R. Turner, M.D., Ph.D.

Brigham and Women’s Hospital | Harvard Medical School

"The polyclonal antibody you generated for KIAA0408 is stunning! KIAA0408 is a novel cilium molecule that has never been studied. So, clearly there will be a lot of demand for it as we have discovered a very interesting finding and the story will be published in a high impact journal. I am strongly inclined to generate monoclonal antibody for this protein too and we should think about patenting it."

Univ.-Prof. Jay Gopalakrishnan PhD

Heinrich-Heine-Universität | Universitätsklinikum Düsseldorf

"Your ARL13B antibody works beautifully!!! We’re so happy to have a cilia-specific antibody made in rat! I can send you high resolution images to be posted on your website."

Julie Craft Van De Weghe, PhD

School of Medicine | University of Washington

"The assay is a homophilic interaction mediated cell adhesion on purified protein (in this case, immobilized purified Pcdhga9 to Pcdhga9 expressed on cell surface). Compared to control, cell adhesion is reduced in the presence of Pcdhga9 monoclonal antibody supernatants!"

Divyesh Joshi, PhD

School of Medicine | Yale University

"The rabbit hybridoma supernatants of anti-APOBEC3 project are tested positive by ELISA, and we are very happy about it! We previously tried a company, Abclone. Their Project "A" has immune response that is <10,000 titer in antiserum, which would explain why there is no positive mAb after fusion. Their project "B" didn't have any immune response in rabbit."

Harshita B Gupta, PhD.

School of Medicine | UT Health San Antonio

"We have tested anti mouse T cell antiserum samples from both rabbits you sent to us.

They worked very well! Thank you!"

Victoria Gorbacheva, PhD.

School of Medicine | Cleveland Clinic

Contact us for questions or custom requests!

Email Us